Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)
Part of paid clinical trials in Goodyear, Arizona.
- Sponsor
- Western Regional Medical Center
- Study ID
- NCT02408042
- Phase
- PHASE1/PHASE2
- Status
- Withdrawn
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Pembrolizumab — DRUG
- Etoposide — DRUG
- Ifosfamide — DRUG
- Mesna — DRUG
- Carboplatin — DRUG
- Brentuximab vedotin — DRUG
- Rituximab — DRUG
Study Details
To determine the recommended phase 2 dose of chemotherapy in combination with Pembrolizumab in subjects with advanced lymphoma and determine the complete response rate.
Key Dates
- Start date
- Apr 30, 2015
- Status verified
- Dec 2015
- Primary completion
- Nov 30, 2015
- Completion
- Nov 30, 2015
Study Design
- Enrollment
- 0 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Active Comparator: RICE and Pembrolizumabnon-Hodgkin's lymphoma patients requiring 2nd line or beyond therapy and eligible to receive RICE (rituximab, ifosfamide, carboplatin, and etoposide)
- Active Comparator: ICE and Pembrolizumabclassical Hodgkin's lymphoma requiring 2nd line or beyond therapy and eligible to receive ICE (ifosfamide, carboplatin, and etoposide)
- Active Comparator: brentuximab vedotin and Pembrolizumabclassical Hodgkin's lymphoma that have progressed after high-dose chemotherapy with autologous stem cell rescue or progressed on at least 2 lines of therapy and are eligible to receive brentuximab vedotin
Primary Outcome Measure
Determine the recommended phase 2 dose (RP2D) of chemotherapy in combination with pembrolizumab (pembro) in subjects with advanced lymphoma and complete remission by Revised Response Criteria for Malignant Lymphoma. [ Time Frame: up to 12 weeks ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Cancer Treatment Center of America @ Western Regional Medical Center | Goodyear | Arizona | 85338 | - |
Find similar trials in Goodyear, AZ
Related Studies
- Long-Term Follow-up StudyEnrolling By Invitation · Caribou Biosciences, Inc. · Birmingham, Alabama
- Exercise as an Immune Adjuvant for Allogeneic Cell TherapiesEARLY_PHASE1 · Recruiting · University of Arizona · Tucson, Arizona
- BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell LymphomaPHASE2 · Recruiting · Christine Ryan · Phoenix, Arizona
- A Study of Carmustine With and Without Ethanol in Subjects With LymphomaPHASE2 · Recruiting · VIVUS LLC · Goodyear, Arizona